Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
Revenue of Ironwood Pharmaceuticals, Inc. (IRWD)
Revenue in 2023 (TTM): $442.74 M
According to Ironwood Pharmaceuticals, Inc.'s latest financial reports the company's current revenue (TTM) is $442.74 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Ironwood Pharmaceuticals, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $442.74 M | $441.16 M | $-924,864,999 | $-948,069,000 | $-1,002,239,000 |
| 2022 | $410.6 M | $409.18 M | $261.44 M | $252.42 M | $175.07 M |
| 2021 | $413.75 M | $412.23 M | $233.33 M | $200.66 M | $528.45 M |
| 2020 | $389.52 M | $386.39 M | $141.9 M | $108.86 M | $106.18 M |
| 2019 | $428.41 M | $404.54 M | $101.13 M | $58.94 M | $-15,314,000 |
| 2018 | $346.64 M | $313.89 M | $-144,452,000 | $-282,368,000 | $-282,368,000 |
| 2017 | $298.28 M | $278.87 M | $-33,116,999 | $-116,937,000 | $-116,937,000 |
| 2016 | $273.96 M | $272.09 M | $-31,295,000 | $-81,708,000 | $-81,708,000 |
| 2015 | $149.56 M | $149.54 M | $-99,943,000 | $-142,669,000 | $-142,669,000 |
| 2014 | $76.44 M | $50.85 M | $-156,121,000 | $-189,618,000 | $-189,618,000 |
| 2013 | $22.88 M | $15.68 M | $-240,081,000 | $-272,812,000 | $-272,812,000 |
| 2012 | $150.25 M | $149.28 M | $-61,240,000 | $-72,624,000 | $-72,624,000 |
| 2011 | $65.87 M | $65.87 M | $-54,786,999 | $-64,849,000 | $-64,852,000 |
| 2010 | $43.86 M | $43.86 M | $-52,998,000 | $-59,355,000 | $-52,981,000 |
| 2009 | $36.1 M | $36.1 M | $-67,277,000 | $-73,608,000 | $-71,185,000 |
| 2008 | $22.22 M | $22.22 M | $-51,848,000 | $-55,031,000 | $-53,874,000 |
| 2007 | $10.46 M | $10.46 M | $-51,166,000 | $-53,160,000 | $-52,752,000 |
| 2006 | $3.14 M | $ | $-35,803,000 | $-37,279,000 | $-37,180,000 |